ABSTRACT
C hest pain is a high-risk chief complaint commonly seen in the emergency department (ED) as cardiopulmonary emergencies such as acute coronary syndrome (ACS) and pulmonary embolism (PE) among others can be life-threatening. Thus, providers often direct a majority of clinical resources toward the timely diagnosis and treatment of these cardiopulmonary emergencies, especially ACS. However, both gender and racial disparities in the emergent evaluation of potential ACS have been identified with respect to the likelihood of ordering electrocardiographs (ECGs), chest x-rays, and initiating cardiac monitoring. 1 In fact, there is a documented 30% decreased probability for African American men to receive these noninvasive diagnostic tests. 1 Further, African Americans with chest pain presenting to the ED have been shown to be less likely to receive laboratory evaluation for ACS and those found to have ACS are also less likely to receive appropriate therapies including percutaneous coronary intervention. 2, 3 Similarly, female patients with chest pain being transported via emergency medical services to the ED have been shown to receive ECGs and aspirin less frequently. 4 They have also been shown to have longer door-to-STEMI activation times. 5 Additionally, even when controlling for possible common confounders there appears to be a gender bias in favor of men receiving cardiac catheterizations compared with women with similar presentations with an odds ratio of 1.72. 6 Women have also been shown to be much less likely to receive counseling with regard to their chest pain diagnostic options as well as referral for stress testing from the ED. 7 In recognition of these disparities professional EM organizations have taken a number of steps to increase awareness and lay out a research agenda to bridge these gaps. For example, the 2014 Academic Emergency Medicine Consensus Conference on GenderSpecific Research in Emergency Care emphasized that all "researchers include gender stratification; make it a requirement for publication." 8 Further, chest pain risk stratification tools that currently appear to systematically categorize women as lower risk for ischemia were identified as a priority area for investigation. 9 With this in mind, the purpose of this study was to test for significant differences in subjective and objective pretest probabilities for ACS in a large cohort of chest pain patients stratified by race or gender. Secondarily we wanted to test for any differences in rates of ACS, rates of 90-day returns, cost, and chest radiation exposure after these stratifications. Our underlying hypothesis was that given what we already know about these disparities, providers would frequently rate risk for ACS in both nonwhite subjects and women to be lower and that there would be concomitantly lower costs and radiation exposure for these groups without difference in rates of ACS and 90-day returns.
METHODS

Study Design
This is a hypothesis-generating secondary analysis of a prospective outcomes study of 851 ED patients presenting to four EDs with chest pain and shortness of breath. All sites had institutional review board approval and written informed consent was obtained from all subjects. The Food and Drug Administration investigational device exemption number is IDE 125834 and the Clinical Trials.gov ID number is NCT01059500. The following analyses rely on the original outcomes study methods, design, and data collection, which have been previously published but will be detailed below. 10 
Study Setting and Population
Between January 2010 through February 2013, data on subjects presenting with chest pain were prospectively collected from four centers including one community hospital (Forsyth Hospital, Winston Salem, NC) and three academic institutions (Beth Israel Deaconess Medical Center, Boston, MA; Carolinas Medical Center Main Hospital, Charlotte, NC; and University of Mississippi Medical Center, Jackson, MS). These centers had annual ED volumes between 70,000-110,000 and were chosen to represent a heterogeneous sample of patients. During the enrollment period, trained research assistants identified potential participants using the electronic tracking board in the ED under a partial waiver of authorization for screening. Enrollment occurred Monday through Saturday with coverage for 16 hours per day. Inclusion criteria consisted of age > 17 with a chief complaint of "chest pain," "chest discomfort," "dyspnea," or "shortness of breath." Additionally, these patients had to have a 12-lead ECG and be able to understand English. However, Spanish-speaking patients were eligible for enrollment with the aid of an interpreter. Exclusion criteria consisted primarily of ECG computer interpretation of "ischemia," recent (within 30 days) or current myocardial infarction (MI) or STEMI; coronary artery bypass grafting within 30 days; known diagnosis of acute PE within the previous 24 hours; cocaine use within previous 72 hours; subjects requiring court-ordered medical clearance, referral to a detoxification center, or physician referral to the ED specifically for admission; individuals visiting from out of town or with other situations thought to be a barrier to follow-up such as homelessness; individuals who were prisoners or in police custody; and pregnant patients. Subjects presenting with acute decompensated heart failure, hemodynamic compromise, altered mental status, psychosis, cerebrovascular accidents, traumatic injury, hemorrhage, sepsis syndromes, unstable arrhythmias, or severe hypoxemia or who were otherwise clearly critically ill were also excluded. Individuals subject to postenrollment exclusion were those who left against medical advice, were subsequently incarcerated within 14 days of their visit, or were objectively cocaine positive by testing. 10 
Measurements
Numerous data points were collected on enrolled subjects as part of the original outcomes study and those relevant to this analysis are detailed below. Pretest probabilities for ACS were assessed both subjectively and objectively. For the subjective assessment, physicians (residents, fellows, and attendings) were presented with a 100-mm visual analog scale (VAS) for likelihood of ACS prior to testing. The physician was instructed to place a vertical mark on the line corresponding to the patient's likelihood of risk for ACS. These marks were measured in centimeters and converted to percentages by multiplying by 10. These clinicians were aware their assessment was being used for research purposes. Objective ACS pretest probabilities were assessed using a validated online tool, PREtest Consult (http://pretestconsult.com/v21/acs). This tool uses attribute matching to estimate the subject's pretest probability for ACS within 45 days based on eight clinical predictors (age, gender, race, chest pain reproduced by palpation, diaphoresis, personal coronary artery disease history, ECG ST depression > 0.5 mm, and ECG T-wave inversion deeper than 0.5mm). 11, 12 Computer software matches this profile of clinical predictors to a data set of greater than 15,000 patients with chest pain and dyspnea. Those with exact profile matches are selected providing both the numerator (number of those with ACS) as well as the denominator of all matches producing a numeric pretest probability value. These values could be further be divided into four risk subgroups (ultralow 0% to < 2.5%, low 2.5% to 5.5%, moderate > 5.5% to 10%, and high > 10%). 10, 13 Subjective pretest probabilities were collected prior to calculation of objective probabilities. Additional outcomes were assessed through systematic chart review and follow-up phone calls at 90 days. They include rates of ACS at 30 days, total radiation exposure to the chest in millisieverts (mSv), total costs at 30 days, and 90-day returns to the ED (including overnight and inpatient admissions). 10 Standard definitions were used in accordance with published guidelines at the time of original study implementation.
14, 15 The definition of MI was "either greater than 0.1 mV of ST-segment elevation in 2 contiguous leads on 12-lead ECG or a troponin I concentration that was above the 99th percentile, with less than 10% coefficient of variability (SD/mean) and with no history of chronic troponin elevation, death thought to be from ACS (autopsy not required), need for revascularization (angioplasty, stent placement, or surgical bypass grafting), or a coronary stenosis on cardiac catheterization greater than 60% not amenable to stent placement and requiring new medical management. A positive stress or nuclear cardiology test result followed by new medical management in the absence of any other criteria was not considered acute coronary syndrome." 10 Data on radiation dosages to the chest including chest radiography, CT scanning, studies using fluoroscopy (e.g., cardiac catheterization, upper gastrointestinal series), and radioisotopic nuclear scanning (egg, cardiac, and ventilation-perfusion scanning) were collected through 90 days. Dosages are reported in millisieverts calculated in accordance with published expert guidelines. 16, 17 Medical cost data associated with in-hospital materials and services through 30 days after initial enrollment were collected from the universal hospital claims submission form (UB-92 CMS-1450). 10 Costs accrued were included regardless of reason and as such was not restricted to only costs associated with the evaluation and management of cardiopulmonary disease processes. The cost-to-charge ratio method was used to convert charges to cost relying on the Medicare impact file to correct for markup. 18 This method excludes professional billing. Finally, returns to the ED including overnight observations and inpatient admissions were assessed through 90 days. Information collected at 90-day follow-up phone calls was confirmed and supplemented with systematic chart review.
Study Protocol
Two separate analyses were performed on this data set. For analysis 1, we divided the database by gender (female vs. male) and compared these two groups on the outcomes described above: provider VAS for likelihood of ACS, PREtest Consult ACS probabilities, rates of ACS, total radiation exposure to the chest, total costs at 30 days, and 90-day recidivism (ED, overnight observations, and inpatient admissions). Analysis 2 divides the database by race (white vs. nonwhite) and examines the same outcome variables. For each analysis, potentially clinically significant confounders or covariates such as age and past medical history (diabetes, hypertension, prior MI, and current smoking status) were taken into account through regression.
Data Analysis
Because this was an unplanned secondary analysis, the original sample size calculation did not take into account this specific clinical question. We did, however, perform this calculation using the population that we had to draw from (851 patients). Our primary objective was to evaluate for a significant difference in ACS pretest probabilities (objective and subjective) when stratifying by either race or gender. To show an effect size of 25% (difference between mean pretest probabilities between groups), assuming a population size of 851 with the standard alpha of 0.05 and beta of 0.2, the sample size needed in each group would need to be 251 for a total of 502, well below the available population of 851 subjects.
Descriptive statistics and analysis of means, medians, frequencies, and proportions were performed using IBM SPSS Version 24 (IBM Corp., released 2013) software. Analysis was performed on nonnormally distributed data using the Mann-Whitney U-test. Proportions were compared using chi-square analysis. We have chosen to present 95% CIs on all data and interquartile ranges (IQR) when relevant. We have also included p-values to be used in context with the 95% CIs for illustration of effect size. Primary analysis was based on univariate comparisons; however, we performed a subsequent analyses taking into account any cofactors or predictors that were not equally distributed between groups. We accomplished this using generalized linear models with binary logistics for the categorical outcomes and the gamma log link for our continuous outcomes. Any missing case variables were excluded from their respective analysis and are noted in Figure 1 .
RESULTS
Of the 851 patients included in the database, six were excluded from evaluation because these individuals either left against medical advice or left before their evaluation was complete. One additional subject was excluded as a duplicate as shown in the CONSORT diagram (Figure 1 ). A total of 844 patients were then eligible for analysis. Gender information was present on all 844 subjects, while complete race demographics were available on 783 (93%) subjects. Figure 1 also shows the number of patients in each stratification along with the proportions with the respective outcome data of interest. Complete participant demographics and outcomes have been previously published.
10 Table 1 provides an overview of patient characteristics and medical history according to each stratification (gender and race) along with p-values for significant differences among groups. In addition to proportions of race and gender in this population, we also report age, smoking status, rates of diabetes, hypertension, and prior MI. For the gender analysis, the only characteristics significantly differences were nonwhite race (59.4% of females vs. 43.6% of males) as well as history of prior MI (5.4% of females vs. 11.9% of males). No significant differences were found between males and females based on age, current smoking status, diabetes, or hypertension. When stratified by race, the only significant differences found among the above-mentioned characteristics were age (46 years old in nonwhites vs. 51 years old in whites) and female gender (64% vs. 48% in nonwhites and whites, respectively). With regard to the providers seeing these patients and providing the VAS, we have complete data on 584 interactions (162 attendings, 15 fellows, and 407 residents). We do not have comprehensive data on provider gender, race, or ethnicity.
Summary data for analysis 1 by gender primarily examining pretest assessments is found in Table 2 showing means, medians, proportions where appropriate, associated 95% CIs, and p-values. Fifty-seven percent (478/844) of patients were female and their mean provider VAS scores for ACS were significantly lower (p = 0.000) at 14% (95% CI = 13% to 16%) than that of males at 22% (95% CI = 19% to 24%). This is consistent with the objective pretest ACS probabilities calculated via PREtest Consult, which were also significantly lower (p = 0.000) at 2.7% (95% CI = 2.4% to 3.1%) for females versus 6.6% (95% CI = 5.9% to 7.3%) for males. Stated another way, 62.1% (297/478) of female subjects had an ultralow (<2.5%) pretest probability while only 37.6% (138/ 367) of males could be categorized as such (p = 0.000). However, with regard to secondary outcomes also shown in Table 2 comparing females to males, there was no significant difference in diagnosis of ACS (3.6% vs. 1.6%), mean chest radiation doses (5.0 mSv vs. 4.9 mSv), or return to the ED within 90 days (26% each). Similarly, no significant differences were found for 90-day observation admissions (1.3% vs. 2%) or inpatient admissions (9% vs. 11%). Total mean costs at 30 days for females was found to be $3,451.24 compared with males at $3,847.68 with a p-value of 0.072. Table 2 also shows associated p-values for each of these outcomes stratified by gender when race and prior MI are taken into account via generalized linear modeling. No changes in status of significance or lack thereof were found after accounting for these two variables not equally distributed between females and males.
When separately stratified by race for analysis 2, shown in Table 3 , nonwhite patients comprised 57% (444/783) of eligible individuals. Mean provider VAS scores for ACS were found to be significantly lower (p = 0.000) at 15% (95% CI = 13% to 16%) for nonwhite versus 20% (95% CI = 18% to 23%) for white subjects. Concordantly, objective pretest ACS probabilities via PREtest Consult were also significantly lower (p = 0.000) at 3.4% (95% CI = 2.9% to 3.9%) for nonwhite versus 5.3% (95% CI = 4.7% to 5.9%) for white subjects. Again, nonwhite subjects had a much higher proportion of patients who could be categorized as having an ultralow pretest probability at 61% (270/444) versus 42% (142/339; p = 0.000). Similar to the previous analysis, there were no significant differences in outcomes in nonwhite versus white subjects when compared on diagnosis of ACS (3.2% vs. 2.4%), mean chest radiation dose (4.6 mSv vs. 5.0 mSv), mean cost ($3,156.02 vs. $2,885.18), or 90-day ED returns (28% vs. 23%) or admissions as shown in Table 3 . Similar to analysis 1, we examined the effect of non-equally distributed characteristics among the two groups by performing a generalized linear model incorporating age and gender. Cost was the only outcome variable that subsequently went from not being significant (p = 0.5) to showing a significant difference (p = 0.026).
DISCUSSION
Over the past 20 years, concerted efforts have been made to identify health disparities based on gender, race, and ethnicity. 19 Additionally, the specialty of emergency medicine has sought to define the key priorities in gender-based research with respect to chest pain and ischemic heart disease among other disparities. 8, 9, 20 However, despite these and other focused efforts like Healthy People 2010, it has been reported that these disparities still persist. 21 Our study sought to determine if these patterns of racial and gender disparities were present in a large cohort of prospectively evaluated chest pain patients presenting to four EDs (two in North Carolina; one in Boston, Massachusetts; one in Jackson, Mississippi) with a heterogeneous population of patients and diverse practice patterns. Each of these hospitals had an ED chest pain observation unit protocol. Unlike previous studies that examined outcomes such as performance of ECG, labs, stress testing, or coronary intervention, for these analyses we were primarily interested in the pretest assessment of ACS risk using total costs and chest radiography as surrogates for level of testing, meaning that those with less total costs or radiation exposure could be assumed to have had less evaluation. Our hypothesis was based on the assumption that providers do not explicitly set out to treat patients differently based on gender or racial background but rather that there are a number of unconscious biases that continue to drive these disparities. 22, 23 Thus the null hypothesis was that that there would be no differences in either subjective or objective pretest probabilities among this cohort when stratified by either gender or race. Additionally, there would be no difference in outcomes including (rate of ACS diagnoses, radiation exposure, costs, and 90-day return rates). However, if differences were found in pretest probabilities, we expected that for providers to remain intellectually congruent, they would offer less testing to patients they perceived to be at lower risk for ACS. Contrary to our null hypothesis, we actually found that after stratification, both female patients and nonwhite patients had significantly lower subjective physician VAS scores for probability of ACS compared with males and white patients, respectively. Across these respective groups, there was an approximate difference of 6%. Although the reason for this consistent underestimation is unclear, intellectually this would actually make sense in the context of what has already been reported regarding disparities in chest pain evaluation and management of both females and nonwhite subjects as well as unconscious biases. 1, 6, 23 This is especially striking as we consider the fact that these providers knew their responses were being recorded for research purposes and still rated women and minorities lower. Given that race and gender comparisons were not the primary reason for this data collection, it is difficult to see how the Hawthorne effect would influence this particular clinical question. If anything, the VAS illustrates the provider's enhanced opinion of ACS risk based largely on his or her experience and preconceived notions to that point which may or may not include conscious assessment of race or gender. Nonetheless, "something" about these patient populations made them appear to be at less risk. For example, it is unclear if this underestimation of risk is based on reported "typical" ACS symptoms or lack thereof. This is important given what we know about the atypical presentation of ACS especially in women. 24, 25 These VAS findings are noteworthy in and of themselves but even more so when compared with the objective ACS pretest probabilities using PREtest Consult. These objective probabilities were concordantly and significantly lower for both minorities and women compared with their counterparts. Put simply, providers consistently estimated level of risk for ACS to be lower prior to evaluation for both females and nonwhite subjects which agreed with objective assessments calculated after this estimation. These significant differences do not change even when accounting for possible confounders in each stratification shown in Table 1 . While PREtest Consult is based solely on objective data as outlined under Methods, it does take into account gender and race as part of its †Wald chi-square (gamma log). ‡PREtest Consult uses attribute matching to produce a numeric pretest probability value that can further be divided into four subgroups (0 to <2.5% ultralow, 2.5% to 5.5% low, >5.5% to 10% moderate, and >10% high). §Fisher's exact chi-square test. ||Wald chi-square (binary logistic).
¶Does not include professional charges.
process of attribute matching. There is evidence that current risk stratification tools can tend to underestimate ACS risk particularly for women. 9 However, this alone would not account for subjective underestimation unless it points to systemic biases perpetuated through medical education and residency training. 26, 27 This is also interesting when we consider that many risk stratification tools use some form of provider gestalt in their calculation, including the recently popular HEART score. 28 Our expectation was that if differences in pretest assessments were found, that the amount of radiation exposure and total costs would concordantly be lower indicating a lower level of testing commensurate with risk level. Instead, we discovered that there was significant overlap of the 95% CIs for both radiation and cost when analyzed either by gender or race, indicating equivalent levels of testing as their companion groups. This is surprising because it appears to indicate that when providers a priori assigned a lower level of risk which was essentially confirmed with objective pretest probabilities there was no effect on provider behavior based on these two outcomes. Further, it is also informative that when looking at significant outcomes presumably important to patients (rates of ACS diagnosis as well as returns to the ED and admissions) there was no differences among analyzed groups. This suggests that ED providers may employ their own standard evaluation for the complaint of chest pain irrespective of pretest probabilities. In other words, there may be a normalization of ACS evaluations across gender and racial groups in response to a number of external pressures: 1) existing efforts at mitigating identified disparities; 19 2) providers' aversion to perceived medicolegal consequences of a missed MI; 29 or 3) local practice patterns encouraging standardized chest pain evaluation. We believe that this tends to fit what we see in practice, that the fear of missing a diagnosis of ACS and its medicolegal consequences overrides judicious use of testing commensurate with risk level. Prospective evaluation specifically powered for stratification of race and gender examining pretest assessments and their correlation with specific evaluation metrics is needed to confirm these results. 1.000 § 0.567|| ACS = acute coronary syndrome; GLM = generalized linear models; VAS = visual analog scale. *Independent-samples Mann-Whitney U-test. †Wald chi-square (gamma log). ‡PREtest Consult uses attribute matching to produce a numeric pretest probability value that can further be divided into four subgroups (0 to <2.5% ultralow, 2.5% to 5.5% low, >5.5% to 10% moderate, and >10% high). §Fisher's exact chi-square test. ||Wald chi-square (binary logistic).
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LIMITATIONS
This was an unplanned secondary analysis of a prospectively collected data set. As such, the original study was not set up to answer this specific question regarding pretest assessment according to race and gender. Thus, the proportions of males to females and racial demographics were not controlled for and are not equivalent. However, it may strengthen the results as females and nonwhites were effectively oversampled. Second, as part of the original database inclusion criteria there had to be both reported chest discomfort and shortness of breath as well as an ordered ECG. Therefore, those who may have had atypical presentations not specifically endorsing those symptoms (primarily "chest pain") would not have been included and it is unclear how their inclusion may have affected the results. Furthermore, since VAS scores were usually obtained after the ECG was ordered, we can make no inferences about how its presence may have impacted further assessment. However, we point out that many EDs have enacted protocols that automatically mandate ECGs even prior to physician assessment for certain chief complaints.
30,31
We also do not have comprehensive information on the demographics of the physicians giving the VAS assessment thus we were not able to quantify what if any impact the race, gender, or level of experience of the provider played in this assessment. Finally, while we do report some outcomes, this analysis was not meant to be a comprehensive outcomes assessment. We were primarily focused on what if any differences there were regarding pretest assessments when stratified by gender or race.
CONCLUSIONS
This study provides a plausible contributor to the evidence regarding unconscious and systemic bias for some of the disparities seen in healthcare particularly the ED evaluation of chest pain. Providers consistently estimated the risk for acute coronary syndrome to be lower for both females and minorities who presented with "chest pain" and dyspnea. The fact that this estimation was concordant with calculated objective pretest assessments is quite interesting. Surprisingly, however, contrary to what we would have expected based on these assessments, there does not appear to have been any significant decrease in subsequent evaluation of these perceived lower-risk groups when radiation exposure and costs are taken into account. Additionally, there were also no differences in rates of acute coronary syndrome or 90-day ED returns for these two comparison groups. However, while these results are extremely interesting and thought provoking, they should be taken in context with what we already know through existing literature on healthcare disparities and be used to work on ways to both decrease these disparities as well as methods of matching our level of evaluation with accurate pretest assessments.
